

NCT00650312 Raw comparison:

Summary:
CHIA has 26 criteria while your personal folder has 27 criteria
Total found criteria: 26/26
Total not Found: 0/26
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Age 18 years and older                             │ Age 18 years and older                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sex Male and non-pregnant non-lactating female     │ Sex Male and non-pregnant non-lactating female     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must have negative │ Women of childbearing potential must have negative │
│ serum (Beta HCG) pregnancy tests performed within  │ serum (Beta HCG) pregnancy tests performed within  │
│ 14 days prior to the start of the study and on the │ 14 days prior to the start of the study and on the │
│ evening prior to each dose administration If       │ evening prior to each dose administration If       │
│ dosing is scheduled on Sunday or Monday the HCG    │ dosing is scheduled on Sunday or Monday the HCG    │
│ pregnancy test should be given within 48 hours     │ pregnancy test should be given within 48 hours     │
│ prior to dosing of each study period An additional │ prior to dosing of each study period An additional │
│ serum (Beta HCG) pregnancy test will be performed  │ serum (Beta HCG) pregnancy test will be performed  │
│ upon completion of the study                       │ upon completion of the study                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must practice      │ Women of childbearing potential must practice      │
│ abstinence or be using an acceptable form of       │ abstinence or be using an acceptable form of       │
│ contraception throughout the duration of the study │ contraception throughout the duration of the study │
│ Acceptable forms of contraception include the      │ Acceptable forms of contraception include the      │
│ following                                          │ following                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (1) intrauterine device in place for at least 3    │ (1) intrauterine device in place for at least 3    │
│ months prior to the start of the study and         │ months prior to the start of the study and         │
│ remaining in place during the study period or (2)  │ remaining in place during the study period or (2)  │
│ barrier methods containing or used in conjunction  │ barrier methods containing or used in conjunction  │
│ with a spermicidal agent or (3) postmenopausal     │ with a spermicidal agent or (3) postmenopausal     │
│ accompanied with a documented postmenopausal       │ accompanied with a documented postmenopausal       │
│ course of at least one year or surgical sterility  │ course of at least one year or surgical sterility  │
│ (tubal ligation oophorectomy or hysterectomy)      │ (tubal ligation oophorectomy or hysterectomy)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ During the course of the study from study screen   │ During the course of the study from study screen   │
│ until study exit - including the washout period    │ until study exit - including the washout period    │
│ women of childbearing potential must use a         │ women of childbearing potential must use a         │
│ spermicide containing barrier method of            │ spermicide containing barrier method of            │
│ contraception in addition to their current         │ contraception in addition to their current         │
│ contraceptive device This advice should be         │ contraceptive device This advice should be         │
│ documented in the informed consent form            │ documented in the informed consent form            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Weight At least 60 kg (132 lbs) for man and 48 kg  │ Weight At least 60 kg (132 lbs) for man and 48 kg  │
│ (106 lbs) for women and within 15% of Ideal Body   │ (106 lbs) for women and within 15% of Ideal Body   │
│ Weight (IBW) as referenced by the Table of         │ Weight (IBW) as referenced by the Table of         │
│ ""Desirable Weights of Adults"" Metropolitan Life  │ ""Desirable Weights of Adults"" Metropolitan Life  │
│ Insurance Company 1999 (See Part II ADMINISTRATIVE │ Insurance Company 1999 (See Part II ADMINISTRATIVE │
│ ASPECTS OF BIOEQUIVALENCE PROTOCOLS)               │ ASPECTS OF BIOEQUIVALENCE PROTOCOLS)               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ All subjects should be judged normal and healthy   │ All subjects should be judged normal and healthy   │
│ during a pre-study medical evaluation (physical    │ during a pre-study medical evaluation (physical    │
│ examination laboratory evaluation 12-lead ECG      │ examination laboratory evaluation 12-lead ECG      │
│ hepatitis B and hepatitis C tests HIV test and     │ hepatitis B and hepatitis C tests HIV test and     │
│ urine drug screen including amphetamine            │ urine drug screen including amphetamine            │
│ barbiturates benzodiazepine cannabinoid cocaine    │ barbiturates benzodiazepine cannabinoid cocaine    │
│ opiates phencyclidine and methadone) performed     │ opiates phencyclidine and methadone) performed     │
│ within 14 days of the initial dose of study        │ within 14 days of the initial dose of study        │
│ medication                                         │ medication                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Institutionalized subjects will not be used 2      │ Institutionalized subjects will not be used 2      │
│ Social Habits                                      │ Social Habits                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any tobacco products                        │ Use of any tobacco products                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ingestion of any alcoholic caffeine- or xanthine-  │ Ingestion of any alcoholic caffeine- or xanthine-  │
│ containing food or beverage within the 48 hours    │ containing food or beverage within the 48 hours    │
│ prior to the initial dose of study medication      │ prior to the initial dose of study medication      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ingestion of any vitamins or herbal products       │ Ingestion of any vitamins or herbal products       │
│ within the 48 hours prior to the initial dose of   │ within the 48 hours prior to the initial dose of   │
│ the study medication                               │ the study medication                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any recent significant change in dietary or        │ Any recent significant change in dietary or        │
│ exercise habits                                    │ exercise habits                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive test for any drug included in the urine   │ Positive test for any drug included in the urine   │
│ drug screen                                        │ drug screen                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medications                                        │ Medications                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any medication within the 14 days prior to  │ Use of any medication within the 14 days prior to  │
│ the initial dose of study medication               │ the initial dose of study medication               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any medication known to alter hepatic       │ Use of any medication known to alter hepatic       │
│ enzyme activity within 28 days prior to the        │ enzyme activity within 28 days prior to the        │
│ initial dose of study medication                   │ initial dose of study medication                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of hormonal contraceptives and hormonal        │ Use of hormonal contraceptives and hormonal        │
│ replacement therapy within three months prior to   │ replacement therapy within three months prior to   │
│ the initial dose of study medication               │ the initial dose of study medication               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diseases                                           │ Diseases                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ a History of any significant chronic disease       │ a History of any significant chronic disease       │
│ and/or hepatitis b History of drug and/or alcohol  │ and/or hepatitis b History of drug and/or alcohol  │
│ abuse c Acute illness at the time of either the    │ abuse c Acute illness at the time of either the    │
│ prestudy medical evaluation or dosing              │ prestudy medical evaluation or dosing              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ d Positive HIV Hepatitis B or Hepatitis C test e   │ d Positive HIV Hepatitis B or Hepatitis C test e   │
│ Renal disease or renal dysfunction (as suggested   │ Renal disease or renal dysfunction (as suggested   │
│ by serum creatinine levels greater than or equal   │ by serum creatinine levels greater than or equal   │
│ to 1 5 mg/dL (for males) and greater than or equal │ to 1 5 mg/dL (for males) and greater than or equal │
│ to 1 4 mg/dL (for females) or abnormal creatinine  │ to 1 4 mg/dL (for females) or abnormal creatinine  │
│ clearance)                                         │ clearance)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Abnormal and clinically significant laboratory     │ Abnormal and clinically significant laboratory     │
│ test results                                       │ test results                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant deviation from the Guide    │ Clinically significant deviation from the Guide    │
│ for Clinically Relevant Abnormalities (see Part II │ for Clinically Relevant Abnormalities (see Part II │
│ ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE           │ ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE           │
│ PROTOCOLS)                                         │ PROTOCOLS)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Abnormal and clinically relevant ECG tracing 6     │ Abnormal and clinically relevant ECG tracing 6     │
│ Donation or loss of a significant volume of blood  │ Donation or loss of a significant volume of blood  │
│ or plasma (> 450 mL) within 28 days prior to the   │ or plasma (\> 450 mL) within 28 days prior to the  │
│ initial dose of study medication                   │ initial dose of study medication                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have received an investigational drug │ Subjects who have received an investigational drug │
│ within 30 days prior to the initial dose of study  │ within 30 days prior to the initial dose of study  │
│ medication                                         │ medication                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Allergy or hypersensitivity to metformin           │ Allergy or hypersensitivity to metformin           │
│ hydrochloride 9 History of difficulty in           │ hydrochloride 9 History of difficulty in           │
│ swallowing medication or any gastrointestinal      │ swallowing medication or any gastrointestinal      │
│ disorder which could affect the drug absorption    │ disorder which could affect the drug absorption    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛